Latest Articles
Where are we with fractionation schedules and prescriptions in high-dose-rate 3D planning vaginal cuff brachytherapy? - Termedia
Where are we with fractionation schedules and prescriptions in high-dose-rate 3D planning vaginal cuff brachytherapy? Termedia
Published: Oct. 17, 2024, 8:03 a.m.
FROM THE LABS: A potentially simpler test and novel therapy for endometriosis - Baylor College of Medicine | BCM
FROM THE LABS: A potentially simpler test and novel therapy for endometriosis Baylor College of Medicine | BCM
Published: Oct. 15, 2024, 3 p.m.
A potentially simpler test and novel therapy for endometriosis - Baylor College of Medicine | BCM
A potentially simpler test and novel therapy for endometriosis Baylor College of Medicine | BCM
Published: Oct. 15, 2024, 3 p.m.
A potentially simpler test and novel therapy for endometriosis - blogs.bcm.edu
A potentially simpler test and novel therapy for endometriosis blogs.bcm.edu
Published: Oct. 15, 2024, 3 p.m.
Progestin-based pharmacotherapy in fertility preservation in early endometrial cancer：A Minireview - Frontiers
Progestin-based pharmacotherapy in fertility preservation in early endometrial cancer：A Minireview Frontiers
Published: Oct. 14, 2024, 11:09 a.m.
Land art is best therapy, artist Jon Foreman says - BBC.com
Land art is best therapy, artist Jon Foreman says BBC.com
Published: Oct. 13, 2024, 2:12 p.m.
The Latest on Targeted Agents, Immunotherapy for Endometrial Cancer - Medpage Today
The Latest on Targeted Agents, Immunotherapy for Endometrial Cancer Medpage Today
Published: July 5, 2024, 7 a.m.
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer - OncLive
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer OncLive
Published: June 24, 2024, 7 a.m.
ASCO 2024: New Insights Into Endometrial Cancer Treatment and Etiology - Cancer Therapy Advisor
ASCO 2024: New Insights Into Endometrial Cancer Treatment and Etiology Cancer Therapy Advisor
Published: June 20, 2024, 7 a.m.
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer Frontiers
Published: June 20, 2024, 7 a.m.
Link copied to clipboard!